血清可溶性清道夫受体CD163含量测定对恶性肿瘤的辅助诊断价值-东南大学学报医学版

血清可溶性清道夫受体CD163含量测定对恶性肿瘤的辅助诊断价值

单位：新疆医科大学附属肿瘤医院检验科, 新疆乌鲁木齐 830011

分类号：R730.43

出版年·卷·期（页码）：2016·35·第四期（534-536）

摘要：

目的：探讨血清可溶性清道夫受体CD163测定在恶性肿瘤临床诊断中的应用价值。方法：收集2014年1月至2014年6月我院收治的恶性肿瘤患者110例（为肿瘤组）以及来我院健康检查的正常人34例（为健康对照组），采用酶联免疫分析法检测两组研究对象血清中sCD163含量，比较两组间血清中sCD163含量差异。采用受试者工作特征曲线评价sCD163含量检测在恶性肿瘤诊断中的应用价值。结果：两组比较，肿瘤组与健康对照组血清中sCD163含量差异有统计学意义（P<0.05）；sCD163提示恶性肿瘤的临界值为90.2 ng·ml^-1，曲线下面积为0.831，敏感度为89.1%，特异度为68.2%。结论：血清sCD163含量测定对恶性肿瘤具有一定的辅助诊断价值，可以作为一种新型的肿瘤标志物。

Objective:To explore the clinical value of soluble scavenger receptor (sCD163) in the diagnosis of malignant tumors. Methods:A total of 110 patients confirmed with malignant tumors and treated in the Affiliated Tumor Hospital of Xinjiang Medical University from January 2014 to June 2014 were selected as tumor group. Thirty-four healthy controls were enrolled as control group.Enzyme-linked immunoassay was employed to determine the levels of sCD163 in the serum of all the subjects. The expression levels of sCD163 in the two groups were compared. The clinical value of sCD163 in the diagnosis malignant tumors was evaluated with receiver-operating characteristic curve (ROC). Results:Compared with the control group, the levels of sCD163 in serum of the tumor group were higher with statistically difference (P<0.05).The diagnosis of malignant tumors could be made when the level of sCD163 reached the critical value of 90.2 ng·ml^-1 and the area under the curve was 0.831. The sensitivity and specificity were respectively 89.1% and 68.2%. Conclusion:sCD163 has certain auxiliary diagnostic value in the diagnosis of malignant tumors and may be considered as a new type of tumor markers.

参考文献：

[1] NIELSEN M J,MOESTRAP S K.Receptor targeting of hemoglobin mediated by the haptoglobins:roles beyond heme scavenging[J].Blood,2009(114):764-771.
[2] van GORP H,DELPUTTE P L,NAUWYNCK H J.Scavenger receptor CD163,a Jack-of-all-Trades and potential target for cell-directed therapy[J].Mol Immunol,2010,47(7/8):1650-1660.
[3] KAZANKOV K,RODE A,SIMONSEN K,et al.Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma[J].Scand J Clin Lab Invest,2015,7:68-77.
[4] MUKHTAR R A,NSEYO 0,CAMPBEU M J,et al.Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics[J].Expert Rev Mol Diagn,2011,11(1):91-100.
[5] BALKWILL F,CHARLES K A,MANTOVANI A.Smoldering and polarized inflammation in the initiation and promotion of malignantdisease[J].Cancer Cell,2005,7(3):211-217.
[6] 邓文龙,邵义明,王俊,等.可溶性髓系细胞触发受体-1和可溶性血红蛋白清道夫受体对脓毒症的诊断价值[J].广东医学,2012,33(20):57-61.
[7] 薛清彬,陈楷正,杨慧婷.脓毒血症患儿血液sCD163变化及其临床意义[J].陕西医学杂志,2013,11(42):1522-1523.
[8] SHABO I,OLSSON H,SUN X F,et al.Expression of the macrophage antigen CDl63 in rectal cancer cells is associated with early local recurrence and reduced survival time[J].Int J Cancer,2009,125(8):1826-1831.
[9] SHABO I,STAL O,OLSSON H,et al.Breast cancer expression of CDl63,a macrophage scavengerreceptor,is related to early distant recurrence and reduced patient survival[J].Int J Cancer,2008,123(4):780-786.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录